- Home
- PHIO vs AIMD Comparison
PHIO vs AIMD Comparison
Compare PHIO & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- AIMD
- Stock Information
- Founded
- PHIO 2011
- AIMD 1984
- Country
- PHIO United States
- AIMD United States
- Employees
- PHIO N/A
- AIMD N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- PHIO Health Care
- AIMD Health Care
- Exchange
- PHIO Nasdaq
- AIMD Nasdaq
- Market Cap
- PHIO 10.2M
- AIMD 11.9M
- IPO Year
- PHIO N/A
- AIMD N/A
- Fundamental
- Price
- PHIO $2.18
- AIMD $3.46
- Analyst Decision
- PHIO Strong Buy
- AIMD
- Analyst Count
- PHIO 3
- AIMD 0
- Target Price
- PHIO $10.67
- AIMD N/A
- AVG Volume (30 Days)
- PHIO 2.7M
- AIMD 7.2M
- Earning Date
- PHIO 08-14-2025
- AIMD 08-13-2025
- Dividend Yield
- PHIO N/A
- AIMD N/A
- EPS Growth
- PHIO N/A
- AIMD N/A
- EPS
- PHIO N/A
- AIMD N/A
- Revenue
- PHIO N/A
- AIMD $110,870.00
- Revenue This Year
- PHIO N/A
- AIMD N/A
- Revenue Next Year
- PHIO N/A
- AIMD N/A
- P/E Ratio
- PHIO N/A
- AIMD N/A
- Revenue Growth
- PHIO N/A
- AIMD 70.25
- 52 Week Low
- PHIO $0.97
- AIMD $2.00
- 52 Week High
- PHIO $9.79
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- PHIO 40.77
- AIMD 60.77
- Support Level
- PHIO $2.03
- AIMD $3.05
- Resistance Level
- PHIO $2.29
- AIMD $3.58
- Average True Range (ATR)
- PHIO 0.16
- AIMD 0.40
- MACD
- PHIO -0.03
- AIMD 0.10
- Stochastic Oscillator
- PHIO 22.39
- AIMD 53.78
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.